Stockscreener 앱 받기
35.39
0.43%
0.15
전일 마감가:
$35.24
열려 있는:
$35.75
하루 거래량:
1.94M
Relative Volume:
0.99
시가총액:
$4.25B
수익:
-
순이익/손실:
$-507.65M
주가수익비율:
-7.6935
EPS:
-4.6
순현금흐름:
$-616.24M
1주 성능:
+7.50%
1개월 성능:
+5.05%
6개월 성능:
-67.01%
1년 성능:
-45.17%
1일 변동 폭
$34.90
$36.71
1주일 범위
$31.27
$36.71
52주 변동 폭
$27.66
$121.06
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
35.39 | 4.25B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - GlobeNewswire
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.47%
2.63%
자본화:
|
볼륨(24시간):